Project description:In this study we compared the expression of 30215 genes in mantle cell lymphoma-initiating cells (MCL-ICs) with mantle cell lymphoma-non-initiating cells (MCL-non-ICs) and B-cells from healthy donor Three samples each of MCL-ICs and MCL-non-ICs were isolated from aphresis of 3 mantle cell lymphoma primary patient samples and 2 samples of CD19+ Bcells isolated from buffy coats of healthy donor Microarray include both coding and non-coding transcripts but only mRNA coding transcript were included in this study.
Project description:In this study we compared the expression of 30215 genes in mantle cell lymphoma-initiating cells (MCL-ICs) with mantle cell lymphoma-non-initiating cells (MCL-non-ICs) and B-cells from healthy donor
Project description:Mantle cell lymphoma gene expression profiling array VFN-M3. The dataset contains data from 10 samples hybridized on Illumina HumanHT-12 array. -patient's primary lymphoma cells obtained from leukemized blood (P6-PBMC1, P6-PBMC2) -non-malignant B-cells isolated from peripheral blood of 5 healthy donors (VFN-M3-CTRL1, VFN-M3-CTRL2) -lymphoma cell line named UPF7U established from the patient's primary lymphoma cells after 166 and 226 days of in vitro cultivation (UPF7U-D166, UPF7U-D226) -cells established by xenotransplantation of UPF7U cell line isolated ex vivo from subcutaneously growing lymphoma (UPF7U-SC) -patient-derived xenograft (PDX) cells named VFN-M3 established by xenotransplantation of primary lymphoma cells into immunodeficient mice isolated ex vivo from the lymph node like tumor (VFN-M3-LN3) -patient-derived xenograft (PDX) cells named VFN-M3 established by xenotransplantation of primary lymphoma cells into immunodeficient mice isolated ex vivo from subcutaneously growing lymphoma (VFN-M3-SC1, VFN-M3-SC3). Samples were sorted using CD19-microbeads (Miltenyi). For xenotransplantation, NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice (referred to as NSG mice) were used.
Project description:MicroRNAs expression profile was acquired in 99 frozen tissues corresponding to 14 Burkitt's lymphoma, 17 diffuse large B-cell lymphoma, 29 follicular lymphoma, 19 mantle cell lymphoma, 8 primary mediastinal B-cell lymphoma and 12 lymph nodes. Additionally, we performed microRNA expression profile of 14 Burkitts' lymphoma cell lines, 2 mantle cell lymphoma cell lines, 5 acute lymphoblastic leukemia cell preparations, 5 samples of mononucleosis cells, 4 Epstein Barr virus infected lymphoblastoid cell lines (EBV), 27 purified samples of B cells at different stage of development (13 GC-CD23-/CD39-, 11 GC-CD5- and 3 GC-CD5+), 4 peripheral blood CD19+ B cells, 4 purified samples of T cells (2 CD4+ and 2 CD8+) and 2 samples of bone marrow CD34+ cells. The data were used to discriminate among diverse pathological and nonpathological samples and to identify microRNAs expression differences between pathological samples and their nonpathological counterparts.
